These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3117570)

  • 21. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
    Itälä M; Pelliniemi TT; Remes K
    Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple myeloma presenting high fever and high serum levels of lactic dehydrogenase, CRP, and interleukin-6.
    Murakami H; Takada S; Hatsumi N; Yokohama A; Saitoh T; Uchiumi H; Maehara T; Matsushima T; Tsukamoto N; Morita K; Tamura J; Sawamura M; Karasawa M
    Am J Hematol; 2000 May; 64(1):76-7. PubMed ID: 10815794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.
    Suki S; Swan F; Tucker S; Fritsche HA; Redman JR; Rodriguez MA; McLaughlin P; Romaguera J; Hagemeister FB; Velasquez WS
    Leuk Lymphoma; 1995 Jun; 18(1-2):87-92. PubMed ID: 8580834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.
    Suguro M; Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
    Am J Hematol; 2000 Oct; 65(2):132-5. PubMed ID: 10996830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
    Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
    Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical markers in multiple myeloma: a multivariate analysis.
    Simonsson B; Källander CF; Brenning G; Killander A; Gronowitz JS; Bergström R
    Br J Haematol; 1988 May; 69(1):47-53. PubMed ID: 3289607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
    Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum thymidine kinase and beta-2 microglobulin in monoclonal gammopathies.
    Ucci G; Riccardi A; Luoni R; Spriano P; Merlini G; Danova M; Cassano E; Molinari E; Ascari E
    Tumori; 1987 Oct; 73(5):445-9. PubMed ID: 3318049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
    Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
    Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial.
    Brown RD; Joshua DE; Nelson M; Gibson J; Dunn J; MacLennan IC
    Br J Haematol; 1993 Jun; 84(2):238-41. PubMed ID: 8398824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biological significance of serum tumor markers in adult T-cell leukemia.
    Sadamori N
    Leuk Lymphoma; 1996 Aug; 22(5-6):415-9. PubMed ID: 8882954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic Value of Corrected Levels of Serum Calcium and Serum Lactate Dehydrogenase for Newly Diagnosed Multiple Myeloma Patients].
    Xie YM; Cui YJ; Li H; Pan XR; Xu YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):844-849. PubMed ID: 31204942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies.
    Bouafia F; Drai J; Bienvenu J; Thieblemont C; Espinouse D; Salles G; Coiffier B
    Bull Cancer; 2004; 91(7-8):E229-40. PubMed ID: 15381461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum deoxythymidine kinase in myelodysplastic syndromes.
    Aul C; Gattermann N; Germing U; Winkelmann M; Heyll A; Runde V; Schneider W
    Cancer; 1994 Jan; 73(2):322-7. PubMed ID: 8293395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
    Cuzick J; Cooper EH; MacLennan IC
    Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
    Anagnostopoulos A; Gika D; Hamilos G; Zervas K; Zomas A; Pouli A; Zorzou M; Kastritis E; Anagnostopoulos N; Tassidou A; Anagnostou D; Dimopoulos MA
    Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.